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Summary
Objective: Puerarin is one of the major phytoestrogens isolated from Pueraria lobata, a Chinese medicine known as Gegen. Our laboratory
compared the amount of new bone produced by puerarin in collagen matrix (carrier) to that produced by the collagen matrix alone.
Method: Eighteen bone defects, 5 mm by 10 mm were created in the parietal bone of nine New Zealand White rabbits. In the experimental
group, six defects were grafted with puerarin solution mixed with collagen matrix. In the control groups, six defects were grafted with collagen
matrix alone (active control) and six were left empty (passive control). Animals were killed on day 14 and the defects were dissected and
prepared for histological assessment. Serial sections were cut across each defect. No new bone was formed in the passive control group.
Quantitative analysis of new bone formation was made on 100 sections (10 sections in each defect, in ﬁve defects randomly selected in
each of the experimental group and active control group) using image analysis.
Results: A total of 554% more new bone was present in defects grafted with puerarin in collagen matrix than those grafted with the collagen
matrix alone.
Conclusion: Puerarin in collagen matrix has the effect of increasing new bone formation locally and can be used for bone grafting or for bone
induction often required in surgery.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.





Bone induction is needed in treating bone trauma and ﬁlling
osseous defects often required for successful surgery. Over
the years autogenous cancellous bone grafting has been
considered the gold standard in replacing bone1. The major
limitations of using autogenous grafting are the inadequacy
of supply and surgical morbidity; including donor site pain,
paresthesia, and infection, which can approach 8e10%2.
Moreover, graft resorption posed a severe problem. In an
experimental study, endochondral bone grafts showed
65% volume loss3. Allografts, an alternative to autogenous
grafting, seem to be biologically inferior and are associated
with infection and inﬂammation4.
The decrease in serum estrogen after menopause is
associated with bone loss and osteoporosis, and estrogen
replacement therapy is considered to be effective in pre-
venting bone loss5. It has been shown that estrogen en-
hances osteoblast differentiation and bone formation6e8
and the conditioned medium of estrogen-treated osteoblast
cultures inhibits osteoclast development9. Thus, estrogen is
one of the most important sex steroids for the maintenance
of bone balance.
Phytoestrogens are plant-derived non-steroidal com-
pounds that bind to estrogen receptors (ERs) and have
estrogen-like activity10. Phytoestrogens are divided into
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addition, some ﬂavonoids, such as naringenin, are also
classed as phytoestrogens10. They have attracted much
attention among public and medical communities because
of their potential beneﬁcial role in prevention and treatment
of cardiovascular diseases, osteoporosis, diabetes and
obesity, menopausal symptoms, renal diseases and various
cancers11,12.
Kanno et al.13 report the effects of phytoestrogens and
environmental estrogens on osteoblast differentiation using
MC3T3-E1 cells, a mouse calvaria osteoblast-like cell line.
They increased alkaline phosphatase activity and en-
hanced bone mineralization in these cells.
Puerarin (Fig. 1), 4H-1-benzopyran-4-one,8-b-D-glueopyr-
anosyl-7-hydroxy-3-(4-hydroxy-phenyl), C12H20C9, is one of
the major phytoestrogens isolated from the root of a wild le-
guminous creeper, Pueraria lobata (Willd.) Ohwi14. This is
a commonly used traditional Chinese medicine known as
Gegen ( ) and has been demonstrated to have effects
on decreasing loss in bone density in ovariectomized
mice15. It also has other important uses on treatment of
fever14, liver diseases16 and cardiovascular diseases17. In
China, P. lobata is also used as a health supplement for
reducing risk factors of cardiovascular diseases. There are
wide application of P. lobata in clinical prescriptions and
dietary supplements18.
It is possible that puerarin may also increase the bone
formation. The signiﬁcance is, puerarin is commonly taken
as a health supplement in dishes and soups in the Asian
meals. Therefore, if puerarin can be shown to increase
bone in an animal model of bone defect healing, it may
be the long-sought-after safe and ideal agent for bone in-
duction and bone defect repair.4
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bone forming ability in vivo for the repair of bone defects by
using a carrier to enable its use in the clinical setting. To
achieve this, our laboratory measured the amount of new
bone produced by puerarin with collagen matrix carrier
grafted into bony defects and compared with that of the col-
lagen carrier alone.
Materials and methods
EXPERIMENTAL AND CONTROL GROUPS
Eighteen 10 5 mm full-thickness bone defects were
created in the parietal bones of nine New Zealand White
rabbits from an inbred colony. The rabbits were 5 months
old (adult stage) and weighed 3.5e4.0 kg. The handling of
the animals and the experimental protocol were approved
by the Committee on the Use of Live Animals in Teaching
and Research, the University of Hong Kong. In the experi-
mental groups, six defects were grafted with puerarin solu-
tion mixed with collagen matrix (as carrier for puerarin). In
the control groups, six defects were grafted with collagen
matrix alone (positive control) and six were left empty (neg-
ative control). The sample size was based on previous
research using this model. Our laboratory uses a small
sample size because there was a large difference in bone
formation between different groups so that statistical sig-
niﬁcant difference can be detected with minimal number
of animals, also from the animal ethic committee that the
smallest sample size that allows a signiﬁcant difference to
be detected should be used.
For the puerarin group and the control groups, two de-
fects were created on the parietal bone of each rabbit. In
each group six defects were created and surgery performed
but after sacriﬁce only ﬁve were randomly drawn and pre-
pared for analyses.
SURGICAL PROCEDURES
The details of the operation and the postoperative care of
the animals were previously described Wong and Rabie19.
In short, the animals were premedicated 1 h before surgery
with oxytetracycline hydrochloride (200 mg/ml, 30 mg/kg
body weight, Tetroxyla, Bimeda, Dublin, Ireland) and bupre-
norphine hydrochloride (0.3 ml/kg body weight, Hypnorm,
Janssen Pharmaceutical, Beerse, Belgium), supplemented
with diazepam (5 mg/ml, 1 mg/kg body weight, valium 10,
Fig. 1. Puerarin.Roche). In order to maintain the level of neuroleptanalgesia,
increments of Hypnorm (0.1 ml/kg) were given at 30-min
intervals during the operation.
The surgical procedure consisted of the creation of one or
two 10 5 mm full-thickness (approximately 2 mm) cranial
defects, devoid of periosteum, using templates, in the parie-
tal bones (Fig. 2). The defects were produced using round
stainless steel burs (1 mm in diameter) on a low speed den-
tal drill. Outlines of the defects were made initially by making
holes of full thickness the parietal bone using a stainless
steel wire template bent to the required size of the defect.
The holes were joined to complete the process. During the
cutting of bone, copious amount of sterile saline was used
for irrigation and to minimize thermal damage to the tissues.
Depending on which groups in which the rabbit belonged,
the defects were grafted with different materials. In the ex-
perimental group, the defects were ﬁlled with puerarin in col-
lagen matrix which consisted of 0.2 ml puerarin solution
(Sigma-Aldrich, MO, USA, dissolved in water for injection
to the concentration of 100 mg/ml) mixed with 0.02 g of col-
lagen matrix (puriﬁed absorbable ﬁbrillar collagen, Collagen
Matrix, Inc., NJ, USA). The grafts were prepared 15 min be-
fore grafting. In the control groups, the defects were either
left alone (negative control) or grafted with 0.02 g of collagen
matrix (puriﬁed ﬁbrillar collagen, Collagen Matrix, Inc., NJ,
USA) mixed with 0.2 ml water for injection (positive control).
POSTOPERATIVE CARE
All wounds were closed with interrupted 3/0 black silk
sutures. No attempt was made to approximate the periosteum
to prevent the barrier effect. Postoperatively, the rabbits were
givenoxytetracyclinehydrochloridedaily for10daysandbupre-
norphine hydrochloride for 2 weeks.
Two weeks after surgery, the animals were killed with
sodium pentobarbitone. Immediately upon death, defects
Fig. 2. Diagram of the dorsal view of the skull of a rabbit, with the
anterior region orientated to the right, showing the sites of two sur-
gically created bone defects on the parietal bones and ﬁve regions
within the defect from which sections were taken for quantitative
analyses. From more than 10 sections cut in each region, two sec-
tions were selected randomly and measured for area new bone
formed, giving a total of 10 sections from each defect. Therefore,
the amount of new bone formation was assessed throughout the
whole defect.
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preparation.
HISTOLOGICAL PREPARATION AND ANALYSIS
Tissues were ﬁxed in 10% neutral buffered formal saline
solution, demineralizedwith K’sDecal Fluid (sodium formate/
formic acid), and ﬁnally double embedded in celloidin/parafﬁn
wax. Each tissue sample containing the defect was embed-
ded intact. Serial, 5-mm-thick sections of the whole defect
were cut perpendicular to the long axis.
Quantitative analysis was made on serial sections of de-
fects in the experimental and the active control groups.
Defects were divided into ﬁve regions spaced 1500 mm
apart (Fig. 2). From the serial sections in each region, two
sections were selected randomly, giving a total of 10 sec-
tions from each defect. Therefore, the amount of new
bone formation was assessed throughout the whole defect.
The total amount of new bone formed (N, Figs. 3 and 4)
within the surgically created defect was measured on 100
sections with a technique previously described by Wong
and Rabie19,20.
Brieﬂy, each section included the graft and host bone of
both sides of the defect. Thus, there were two graftehost
interfaces. The total amount of new bone (N, Figs. 3 and 4)
formed in both graftehost interfaces within the surgically
created defect was quantiﬁed by one observer (blinded e
who did not know which group he was measuring), by out-
lining the periphery of the newly formed bone image in the
computer screen (Leica Qwin Image Processing & Analysis
Software, V2.3, Leica Microsystems Imaging Solutions,
Ltd., UK) using a transmitted light microscope (Leica,
DMLB, Germany) ﬁtted with a video camera (Single CCD
Color Camera, Tk-C1380E, JVC, Japan). Differences in
staining properties and morphology between newly formed
bone and mature bone made identiﬁcation easy (Figs. 3
and 4). The computer image analysis system then calcu-
lated the area of the outlined new bone.
STATISTICAL METHODS
Data were analyzed using a statistical analysis computer
software (Graphpad Instat, v.2.04a, 1993, San Diego, CA,
USA). The one-way analysis of variance (ANOVA) method
was used to compare sections drawn from the ﬁve regions
in each defect. The arithmetic mean, standard deviation
(SD) and 95% conﬁdence intervals were calculated for
each experimental group. The means (puerarin group and
control group) were compared by the Welch’s unpaired
Fig. 3. Photomicrograph showing healing of a bony defect grafted
with puerarin in collagen matrix on day 14. New bone (N) can be
seen spanning the defect. H¼Host bone. Some collagen matrix
(C) remained at the center of the bony defect (Periodic acideSchiff
stain, original magniﬁcation 40).t test which does not assume equal variances, with
P< 0.05 chosen as the critical level of statistical signiﬁcance.
The size of the method error in digitizing the areas of new
bone was calculated by the formula  ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP d 2=2np , where
d was the difference between the two registrations of
a pair and n was the number of double registrations. The
size of the method error is 0.014 mm2. Ten randomly drawn
histological sections were digitized on two separate occa-
sions at least 3 months apart by the same observer and
also by an independent observer. Paired t tests were also
performed to compare the intra-observer and the inter-
observer registrations. The two-tailed P value to compare
the intra-observer registrations was 0.5652, that to compare
the inter-observer registrations was 0.5911, both consid-
ered not signiﬁcant.
Results
CLINICAL AND PHYSICAL EXAMINATIONS
All animals remained in excellent health throughout the
course of the experiment and recovered rapidly after oper-
ation. There was no evidence of side effects or infection
in any of the animals.
HISTOLOGICAL FINDINGS
Experimental group: In the group grafted with puerarin in
collagen matrix, new bone was formed at the host bonee
graft interface and tended to grow across the defect
(Fig. 3). Integration of the puerarin and collagen with the re-
cipient bed was characterized by the presence of new bone.
No cartilage was found. At higher magniﬁcation (Fig. 5),
new bone could be seen growing around a collagen matrix
fragment and tended to grow toward and amalgamate with
the collagen matrix, bone cells were present showing that
the collagen was not just calciﬁed, rather, new bone was
formed.
Control groups: In the active control group little new bone
was formed at the host boneegraft interface. Some collagen
ﬁbers were present at the center of the defects (Fig. 4). In the
passive control group, the defect was healed, with ﬁbrous
tissue bridging across the defect. Very little new bone had
formed at the ends of the host bone, so no quantitative
analysis was performed.
The newly formed bone was woven bone and histologi-
cally looked similar in different groups, bone cells could
be seen so they were not just calciﬁcations, it was more
abundance near the ends of the bone defect. In the puerarin
group it tended to grow toward the collagen matrix where
puerarin was added.
Fig. 4. Photomicrograph of defect grafted with collagen matrix (pos-
itive control) in day 14. No bone could be seen across the defect
except for a little new bone (N) near the ends of the host bone
(H). Collagen matrix (C) remained across the bone defect (Periodic
acideSchiff stain, original magniﬁcation 40).
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A total of 100 sections of the experimental group and the
active control group were digitized and analyzed.
The amount of newly formed bone was signiﬁcantly
greater in the defects grafted with puerarin in collagen ma-
trix than in those grafted with collagen matrix only (Tables I
and II), (Fig. 6). In the experimental group, 50 sections were
measured; the mean area of newly formed bone in each de-
fect was 2.68 mm2, with a SD of 0.6460 mm2. In the active
control group, 50 sections were measured; the mean area
of newly formed bone in each defect was 0.41 mm2, with
a SD of 0.2728 mm2. Welch’s unpaired t test which does
not assume equal variances was used to test the difference
between the two groups, the two-tailed P value is <0.0001,
considered signiﬁcant.
Fig. 5. High power photomicrograph showing the formation of new
bone in a bony defect grafted with puerarin in collagen matrix. New
bone (N) and osteocytes (O) could be seen growing around the col-
lagen matrix (C). Capillaries (cap) were present. No cartilage was
found (Periodic acideSchiff stain, original magniﬁcation 200).
Table I
Comparison of amounts of new bone (mm2) in five defects grafted
with puerarin in collagen matrix. Mean and SD of the 10 sections of
each defects, and results of ANOVA (degree of freedom [df], F, P)
comparing five regions within each defect
Region Defect 1 Defect 2 Defect 3 Defect 4 Defect 5
A 4.21 2.94 2.29 2.75 2.01
3.61 2.76 2.15 3.08 2.03
B 2.92 3.04 2.37 2.89 2.08
2.85 2.93 2.31 3.07 1.97
C 3.89 3.15 2.79 2.68 2.26
2.65 3.32 2.72 2.73 2.37
D 3.23 3.46 2.02 3.11 1.76
2.74 3.56 1.88 2.99 1.68
E 3.44 3.11 1.47 2.40 1.58
3.26 3.42 1.71 2.51 1.46
Mean 3.28 3.169 2.171 2.821 1.92
SD 0.5140 0.2626 0.4176 0.2479 0.2938
df 4,5 4,5 4,5 4,5 4,5
F 1.483 7.395 36.012 6.869 41.525
P 0.3335 0.025 0.001 0.029 0.001Discussion
Our laboratory demonstrated that puerarin in collagen
matrix signiﬁcantly increased new bone formation locally
when grafted into skull defects. It produced 554% more
new bone than the absorbable collagen sponge alone
(active control) (Figs. 3e6). The difference was signiﬁcant
(P< 0.0001, unpaired t test). This comparison showed
that puerarin was osteogenic when used with collagen ma-
trix. It is important to understand the underlying mecha-
nisms of this effect.
As mentioned, puerarin is an isoﬂavone phytoestrogen.
Isoﬂavones stimulate osteogenesis at low concentrations
and inhibit osteogenesis at high concentrations in osteo-
blasts and osteoprogenitor cells21,22. Isoﬂavones also inﬂu-
ence the production of cytokines derived from osteoblasts
and osteoprogenitor cells in a similar biphasic manner23.
Table II
Comparison of amounts of new bone (mm2) in five defects grafted
with collagen matrix (positive control). Mean and SD of the 10 sec-
tions of each defects, and results of ANOVA (degree of freedom
[df], F, P) comparing five regions within each defect
Region Defect 1 Defect 2 Defect 3 Defect 4 Defect 5
A 0.68 0.64 0.18 0.12 0.41
0.74 0.82 0.18 0.11 0.42
B 0.57 0.68 0.15 0.31 0.29
0.51 0.71 0.16 0.38 0.34
C 0.70 0.85 0.35 0.23 0.31
0.70 0.96 0.32 0.18 0.35
D 0.58 0.86 0.20 0.22 0.07
0.74 0.95 0.21 0.24 0.08
E 0.60 0.51 0.06 0.15 0.11
0.80 0.62 0.06 0.13 0.09
Mean 0.662 0.76 0.187 0.145 0.247
SD 0.09223 0.1503 0.09393 0.07412 0.1431
df 4,5 4,5 4,5 4,5 4,5
F 1.379 6.494 179.23 34.071 96.734
P 0.3603 0.0324 <0.0001 0.0008 <0.0001






Fig. 6. Comparison of areas (mm2) of newly formed bone between
defects grafted with collagen matrix (A, 0.41, SD¼ 0.2728), areas
of defects grafted with puerarin in collagen matrix (B, 2.68,
SD¼ 0.6460).
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activity24.
Pettersson et al.25 and An et al.26, proposed the molecu-
lar mechanisms of the osteogenic effects of phytoestrogens
based on their ERs-mediated and/or enzyme-inhibiting ef-
fects. ER-mediated action has focused on the preferential
binding of phytoestrogens to ERb, which acts as a domi-
nant-negative regulator of estrogen signaling. In addition,
some phytoestrogens inhibit tyrosine kinases, and mitogen-
activated protein kinases, which are crucial for cellular func-
tions27. However, the biological effects of phytoestrogens
cannot be fully explained by these mechanisms28.
Dang et al.21 identiﬁed peroxisome proliferator-activated
receptors (PPARs) as additional molecular targets of phy-
toestrogens22. Regardless of their enzyme inhibitory ac-
tions, phytoestrogens can dose dependently activate
PPARs and induce divergent effects on osteogenesis and
adipogenesis. As a result, the balance between concur-
rently activated ERs and PPARs determines the dose-
dependent biological effects of phytoestrogens. As shown
in their studies, dominant ER-mediated effects (an increase
in osteogenesis and a decrease in adipogenesis) could only
be seen at low concentrations of phytoestrogens, whereas
dominant PPARg-mediated effects (a decrease in osteo-
genesis and an increase in adipogenesis) were only evident
at high concentrations.
Phytoestrogens can target Runx2 transcription factor and
PPARg, via binding and/or phosphorylation, resulting in the
commitment of osteoprogenitor cells to differentiate into ei-
ther osteoblasts or adipocytes21,29.
Bone morphogenetic protein-2 (BMP-2), a potent inducer
of osteogenic differentiation, is a target for estrogen and iso-
ﬂavones30,31. Similar to estrogen, isoﬂavones increased the
expression of messenger RNA encoding BMP-2 in mouse
bone marrow mesenchymal stem cells, in C3H10T1/2 cells
and in primary rat osteoblastic cells30,31. These effects are
probably mediated by ERb, and not ERa31.
Further research on various gene expressions in osteo-
blasts, mesenchymal cells and endothelial cells during the
early healing of puerarin in collagen matrix is needed to
conﬁrm the mechanism of its osteogenic effect.
The rabbit model used in this study was relevant because
non-grafted control bone defects have been found not to
heal with new bone formation within 14 days after their cre-
ation. In addition, there was minimal bone healing across
the defect with collagen matrix as shown by the results of
the control group (Fig. 4). There was minimal morbidity
due to this procedure as all the rabbits were in good health
and condition after the surgery. Two weeks was chosen to
examine the bone formation during the early healing of the
bone defect was based on another study32. It gave better
indication of the ability of new bone to grow across the
bone defect. It was also the time span chosen for other
studies on bone formation using the same animal
model19,20,33,34 so that comparisons can be made.
The results of the ANOVA of the different regions within
each defect showed the necessity to analyze multiple re-
gions within each defect (Tables I and II). This was indi-
cated by the P value, the difference in the amount of new
bone formed between the different regions within each de-
fect was statistically signiﬁcant in many defects. There
was variability because the two sections in each region to
be measured were randomly selected among the serial sec-
tions. Despite the variations in the amount of bone forma-
tion in different regions and in different defects, the
amount of bone formation of the puerarin group was greater
than that in the control groups.Collagen matrix (puriﬁed absorbable ﬁbrillar collagen) was
used in this study because it had been used successfully as
a carrier for growth factors like BMP-2 to induce bone forma-
tion in animals and in humans35e37. It was derived from
bovine tendon, in the ﬁbrillar form and was suggested from
the Manufacturer (Collagen Matrix, Inc., NJ, USA) to be
useful for delivering cells and growth factors and for gene
therapy. Recently, it was successfully used with rhBMP-2
in the repair of alveolar clefts in humans38. Bouxsein
et al.39 assessed the retention time of 125IrhBMP-2 in ab-
sorbable collagen sponge using gamma scintigraphy and
showed that about 37 (10)% of the initial dose remained
at the site 1 week after surgery, and 8 (7)% remained after
2 weeks. It is possible that puerarin could have been re-
tained similarly by the collagen matrix carrier and released
over time to exert their effect that led to an increase in
bone formation.
The dose for puerarin in this study was estimated from
a clinical study using puerarin injection40, by multiplying
the dose for human with the body mass ratio between rabbit
and human. Using pilot study this estimated dose did
caused an increase in bone formation. In this study we
have tried to demonstrate the osteogenic effect of puerarin
using one commonly used carrier for bone repair. Further
research is needed to determine the optimum dose, best
choice of carrier and the release kinetics of puerarin in dif-
ferent carriers for bone grafting.
This study has considerable signiﬁcance as puerarin is
a commonly used health supplement in Asia. It gained inter-
ests in research by its multiple health maintenance effects.
This is the ﬁrst study that demonstrated its local osteogenic
effect. Puerarin has tremendous potential to be utilized in
any application that requires increase in bone formation.
Further studies are needed to determine the systemic effect
of puerarin on bone metabolism, for example, on the pre-
vention of osteoporosis.
Conclusion
Puerarin in collagen matrix has the effect of increasing
new bone formation locally and can be used for bone graft-
ing or for bone induction. Further research is needed to op-
timize its use and to gain further understanding on its bone
forming mechanism.
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